Lamisil Articles
Strong Ph II results for Celtic nail fungus agent
30 March 2009
Novartis drops NexMed anti-fungal nail treatment
1 September 2008
HalcyGen's SUBA-Itraconazole in commercial production
24 March 2008
Enrollment "well on track" for Ph III TLT trial
28 January 2008
3rd-qtr global pharmaceutical R&D pipeline report from Fitch
17 December 2007
Beximco starts shipping drugs to Hong Kong
10 September 2007
Actavis launches generic terbinafine in USA
26 July 2007
Novartis progresses NM100060 using NexMed's NexACT
16 July 2007
US FDA approves generic Lamisil
9 July 2007
Talima raises $19M in series B funding round
4 June 2007
Perrigo's generic terbinafine cleared in USA
14 August 2006
Dr Reddy's boosted by acquisitions
12 June 2006
Dr Reddy's of India sees revenues grow 25% and earnings rocket in fiscal third quarter
6 February 2006
NexMed's nail fungus lacquer passes Ph I
5 September 2005
Tentative FDA appro for Ranbaxy and Aurobindo
4 July 2005
Novartis prevails in Lamisil patent dispute with Dr Reddy's
13 September 2004
Gedeon Richter sees product mix improve in 2002
21 April 2003
Stock Commentary - Europe
29 July 2002
Dr Reddy's files for generic Lamisil in USA
29 July 2002
Double-digit turnover growth for Novartis in 2001
11 February 2002
Double-digit turnover growth for Novartis
11 October 2001
UK MCA proposes POM-to-P switches
16 August 2001
Novartis' six-month 2001 net income jumps 10%, sales up 11%
16 August 2001
FDA issues warning on antifungal safety
10 May 2001
Novartis 1st qtr pharma sales rise 13%
19 April 2001
US HMOs reveal their most-accepted drugs
5 April 2001
Novartis expects five new products to drive growth in 2001
15 February 2001
Novartis files ASM 981 for eczema in the USA
18 December 2000
Novartis puts in solid 1st-half performance
21 August 2000
German OTC switches
4 August 2000
Rx to OTC switch for Novartis' Lamisil solution
3 April 2000
Novartis says 25% chance Zelmac NDA will not be accepted
22 February 2000
Novartis 1998 sales down on forecasts
21 January 1999
Selecting Diseases Suitable For OTC Treatment
4 December 1998
Antifungal Drugs In USA Boosted By DTCs
18 September 1998
Novartis Restructures After Disappointing First Half
1 September 1998
First Operational Year Strong At Novartis
19 March 1998
DTC Ads On Television Effectiveness Studied
30 December 1998
Novartis' Nine-Month Drug Sales Climb 26%
30 October 1997
UK Industry Code Of Practice Report
1 September 1997
Strong Pharmaceutical Growth Drives Novartis
24 July 1997
Health Care Fuels Strong 1997 Start For Novartis
21 April 1997
1996 A Demanding Year For Novartis
19 March 1997
Sales Advance 8% In 1996 At Novartis
3 February 1997
Zocor "Will Be World's Top-Selling Drug In 2005"
13 January 1997
Dutch Government Reimbursement Blacklist Rises To 35
9 December 1996
Novartis Partners 9 Months Figures Disappoint
28 October 1996
Dilemma For Imported Drugs In China
5 August 1996
Lamisil approved in USA
20 May 1996
....Nutrition Downturn And Currency Holds Sandoz Back
29 April 1996
Novartis Pipeline: A Good Fit But Cuts Are Expected
18 March 1996
Novartis Pipeline: A Good Fit But Cuts Are Expected
18 March 1996
Sandoz 9 Months Sales up 6%
6 November 1995
USA Lags Foreign Approvals, PhRMA Demonstrates
16 October 1995
Sandoz Half-Year Sales Up 6%, But Pharma Down 2%
24 July 1995
Sandoz Demergers To Focus On Pharmaceuticals
3 April 1995
Dutch Govt Has Mistaken Impression Of Drug Prices
13 March 1995
Sandoz' 1994 Sales Advance 11%
23 January 1995
UK POM-To-P Switches At End-1993
2 January 1995
3% Increase In Sales For Sandoz
31 October 1994
Improvement At Sandoz in 1994 1st Half
12 September 1994
SOLID VOLUME GROWTH HELPS SANDOZ' SALES
25 July 1994
Sandoz Launch In France
18 July 1994
UNCERTAINTY OVER SWEDISH OTC PLANS
9 May 1994
NIZORAL TOPS SKIN DRUG LEAGUE IN 1992
10 January 1994
SALES UP IN 1st NINE MTHS AT SANDOZ
25 October 1993
NEW DATA ON SANDOZ' LAMISIL VS SPORANOX
4 October 1993
SANDOZ LAUNCHES LAMISIL IN JAPAN
27 September 1993
SUSTAINABLE EARNINGS GROWTH FOR SANDOZ
16 August 1993
SANDOZ POSTS STRONG NET INCOME
26 July 1993
UK INDUSTRY CODE OF PRACTICE REVIEW
19 July 1993
BROAD SPECTRUM WAY FORWARD IN ANTIFUNGALS
12 April 1993
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
